Improved radiopharmaceutical delivery system and use thereof for patient infusion
US-2024325628-A1 · Oct 3, 2024 · US
US9687600B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9687600-B2 |
| Application number | US-201514974534-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 18, 2015 |
| Priority date | Nov 29, 2010 |
| Publication date | Jun 27, 2017 |
| Grant date | Jun 27, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0, the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5, and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition.
Opening claim text (preview).
The invention claimed is: 1. An infusion preparation comprising two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion comprising a sugar and a fat emulsion; a second chamber contains a second-chamber infusion comprising an amino acid and an electrolyte; the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0; the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5; and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition; and the volume ratio of the first-chamber infusion to the second-chamber infusion is 3:2 to 3:3. 2. The infusion preparation according to claim 1 wherein the first-chamber infusion has a pH of 4.5 to 6.5, and the second-chamber infusion has a pH of 6.0 to 7.4. 3. The infusion preparation according to claim 1 , wherein the first chamber further contains vitamin B1. 4. The infusion preparation according to claim 2 , wherein the first chamber further contains vitamin B1. 5. The infusion preparation according to claim 3 , wherein the first-chamber infusion further contains vitamin A, vitamin B6, vitamin B12, vitamin D, vitamin E, and vitamin K, and the second-chamber infusion further contains vitamin C and vitamin B2. 6. The infusion preparation according to claim 4 , wherein the first-chamber infusion further contains vitamin A, vitamin B6, vitamin B12, vitamin D, vitamin E, and vitamin K, and the second-chamber infusion further contains vitamin C and vitamin B2.
Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) · CPC title
Nutrients, e.g. vitamins, minerals · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203) · CPC title
one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.